- First to demonstrate single dose, in vivo results, showing approximately a 97 percent reduction in serum transthyretin
protein levels
- Durability data show stable liver editing for at least four months
- Increased liver editing efficiency reported to date at 70 percent, following a single dose
CAMBRIDGE, Mass., March 08, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company
focused on the development of potentially curative therapies, today reported updated data showing increased levels of genome
editing efficiency in vivo and durability results with its CRISPR/Cas9 technology, following a single administration.
Using its lipid nanoparticle (LNP) technology, Intellia achieved approximately a 97 percent reduction in serum transthyretin (TTR)
protein driven by 70 percent gene editing efficiency in the mouse liver.
“These results are extremely promising, as they demonstrate compelling activity with lipid nanoparticles observed
in the liver following a single dose,” said Executive Vice President, R&D John Leonard, M.D. “We are excited by the extent of
the effect, which confirms the power of CRISPR/Cas9 for potential therapeutic uses. These high levels of gene editing are the
result of Intellia’s effort to identify highly efficient delivery of CRISPR/Cas9 using lipid nanoparticles. The data advance our
efforts as we look to transform the way we treat disease.”
The data are being presented for the first time at the Cowen and Company 37th Annual Health Care Conference in Boston on Wednesday,
March 8, 2017 at 8:40 am ET. Complete data are being presented on March 22, 2017 at the Le Stadium Conference on Messenger RNA
Therapeutics in Orleans, France. Data showed robust editing and sustained results including:
- Progress in achieving in vivo gene editing in the TTR locus, with an efficiency of approximately 70 percent in the
total mouse liver at the target DNA site, after a single intravenous administration (versus previously reported 60 percent);
- An associated decrease in serum TTR protein levels of up to approximately 97 percent (versus previously reported 80
percent);
- Undetectable Cas9 mRNA and guide RNA (gRNA) in the liver for 72 hours post administration; and
- Durable and stable liver editing for at least four months following a single administration.
Study Background
The ongoing, preclinical editing studies were designed to explore the use of lipid nanoparticles for delivery of CRISPR/Cas9
components to the liver in mice and to mediate editing of target DNA within hepatocytes. For the LNPs in the studies, Cas9 mRNA was
co-formulated with chemically synthesized gRNAs targeting the mouse TTR gene, and administered via one intravenous tail vein
injection. Additional studies were performed to evaluate the impact of editing of variables in guide format, degree of guide
chemical modification, and dose response on editing efficiency. The durability of the liver editing was evaluated through a
four-month time period, and pharmacokinetic (PK) parameters for Cas9 mRNA and sgRNA were measured.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative
therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by
permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific,
technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position
to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more
about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward looking statements include, but are not limited to, express or implied statements regarding our ability to
advance CRISPR/Cas9 into therapeutic products for severe and life-threatening diseases; the potential timing and advancement of our
clinical trials; the potential targets or indications we may pursue; and potential commercialization opportunities for product
candidates. Any forward-looking statements in this press release are based on management's current expectations of future events
and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from
those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited
to, the risk that any one or more of our product candidates will not be successfully developed and commercialized, the risk that
positive results from a preclinical or clinical study may not necessarily be predictive of the results of future preclinical or
clinical studies, risks related to our ability to protect and maintain our intellectual property position, the risk of cessation or
delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results
of previously conducted studies involving similar product candidates will not be repeated or observed in ongoing or future studies
involving current product candidates, and the risk that our collaboration with Novartis or Regeneron will not continue or
will not be successful. For a discussion of other risks and uncertainties, and other important factors, any of which could cause
our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our
most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission, as well as discussions of potential
risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the date of the release, and Intellia Therapeutics undertakes no
duty to update this information unless required by law.
Intellia Contacts: Media Contact: Jennifer Mound Smoter Senior Vice President, External Affairs & Communications +1 857-706-1071 jenn.smoter@intelliatx.com Investor Contact: Graeme Bell Chief Financial Officer +1 857-706-1081 graeme.bell@intelliatx.com
